logo-loader
viewPropanc Biopharma Inc

Propanc at final stages of completing manufacturing steps to file first clinical trial application

Propanc Biopharma, Inc. (OTCQB: PPCB) CEO James Nathanielsz sat down with Proactive Investors at the BIO CEO and Investor Conference in New York.

The biopharmaceutical company is developing new cancer treatments initially for patients suffering from pancreatic, ovarian and colorectal cancers.

Quick facts: Propanc Biopharma Inc

Price: 0.845 USD

OTCMKTS:PPCB
Market: OTCMKTS
Market Cap: $971.12 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Propanc Biopharma Inc named herein, including the promotion by the Company of Propanc Biopharma Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Propanc Biopharma boosts its patent portfolio for its anti-cancer therapy

Propanc Biopharma Inc (OTCMTKS:PPCBD) CEO James Nathanielsz tells Proactive Investors the company has boosted its intellectual property portfolio for its anti-cancer technology currently in development. The biopharmaceutical company’s portfolio now has 65 patents either in force or...

on 06/28/2019

2 min read